These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 30744705)

  • 1. Neuroinflammation and fractalkine signaling in Alzheimer's disease.
    Finneran DJ; Nash KR
    J Neuroinflammation; 2019 Feb; 16(1):30. PubMed ID: 30744705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CNS-Wide over Expression of Fractalkine Improves Cognitive Functioning in a Tauopathy Model.
    Finneran DJ; Morgan D; Gordon MN; Nash KR
    J Neuroimmune Pharmacol; 2019 Jun; 14(2):312-325. PubMed ID: 30499006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.
    Lee S; Varvel NH; Konerth ME; Xu G; Cardona AE; Ransohoff RM; Lamb BT
    Am J Pathol; 2010 Nov; 177(5):2549-62. PubMed ID: 20864679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer's Disease.
    Bivona G; Iemmolo M; Ghersi G
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulated fractalkine (FKN) and its receptor CX3CR1 are involved in fructose-induced neuroinflammation: Suppression by curcumin.
    Xu MX; Yu R; Shao LF; Zhang YX; Ge CX; Liu XM; Wu WY; Li JM; Kong LD
    Brain Behav Immun; 2016 Nov; 58():69-81. PubMed ID: 26765996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically enhancing the expression of chemokine domain of CX
    Bemiller SM; Maphis NM; Formica SV; Wilson GN; Miller CM; Xu G; Kokiko-Cochran ON; Kim KW; Jung S; Cannon JL; Crish SD; Cardona AE; Lamb BT; Bhaskar K
    J Neuroinflammation; 2018 Sep; 15(1):278. PubMed ID: 30253780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.
    Subbarayan MS; Joly-Amado A; Bickford PC; Nash KR
    Pharmacol Ther; 2022 Mar; 231():107989. PubMed ID: 34492237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway.
    Lee S; Xu G; Jay TR; Bhatta S; Kim KW; Jung S; Landreth GE; Ransohoff RM; Lamb BT
    J Neurosci; 2014 Sep; 34(37):12538-46. PubMed ID: 25209291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.
    Szukiewicz D
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.
    Pawelec P; Ziemka-Nalecz M; Sypecka J; Zalewska T
    Cells; 2020 Oct; 9(10):. PubMed ID: 33065974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson's disease: Potential clinical and therapeutic implications.
    Angelopoulou E; Paudel YN; Shaikh MF; Piperi C
    Pharmacol Res; 2020 Aug; 158():104930. PubMed ID: 32445958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy.
    Nash KR; Lee DC; Hunt JB; Morganti JM; Selenica ML; Moran P; Reid P; Brownlow M; Guang-Yu Yang C; Savalia M; Gemma C; Bickford PC; Gordon MN; Morgan D
    Neurobiol Aging; 2013 Jun; 34(6):1540-8. PubMed ID: 23332170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis.
    Lastres-Becker I; Innamorato NG; Jaworski T; Rábano A; Kügler S; Van Leuven F; Cuadrado A
    Brain; 2014 Jan; 137(Pt 1):78-91. PubMed ID: 24277722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing fractalkine/CX3CR1 signalling pathway can reduce neuroinflammation by attenuating microglia activation in experimental diabetic retinopathy.
    Jiang M; Xie H; Zhang C; Wang T; Tian H; Lu L; Xu JY; Xu GT; Liu L; Zhang J
    J Cell Mol Med; 2022 Feb; 26(4):1229-1244. PubMed ID: 35023309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentration and proteolysis of CX3CL1 may regulate the microglial response to CX3CL1.
    Finneran D; Li Q; Subbarayan MS; Joly-Amado A; Kamath S; Dengler DG; Gordon MN; Jackson MR; Morgan D; Bickford PC; Smith LH; Nash KR
    Glia; 2023 Feb; 71(2):245-258. PubMed ID: 36106533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of inflammatory responses by fractalkine signaling in microglia.
    Inoue K; Morimoto H; Ohgidani M; Ueki T
    PLoS One; 2021; 16(5):e0252118. PubMed ID: 34019594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia.
    Cotter R; Williams C; Ryan L; Erichsen D; Lopez A; Peng H; Zheng J
    J Neurovirol; 2002 Dec; 8(6):585-98. PubMed ID: 12476352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage.
    Sheridan GK; Murphy KJ
    Open Biol; 2013 Dec; 3(12):130181. PubMed ID: 24352739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.